These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 22335311)

  • 1. The importance of physicians identifying and reporting adverse drug events.
    Gatti JC
    Am Fam Physician; 2012 Feb; 85(4):318. PubMed ID: 22335311
    [No Abstract]   [Full Text] [Related]  

  • 2. Report every adverse drug reaction! We're all in this together.
    Griffin GC; Parkinson RW; Woolley BH
    Postgrad Med; 1997 Apr; 101(4):13-6. PubMed ID: 9126202
    [No Abstract]   [Full Text] [Related]  

  • 3. Monitoring for adverse drug events.
    Kennedy DL; Goldman SA
    Am Fam Physician; 1997 Nov; 56(7):1718, 1721. PubMed ID: 9371003
    [No Abstract]   [Full Text] [Related]  

  • 4. FDA Adverse Event Reporting System: Recruiting Doctors to Make Surveillance a Little Less Passive.
    Mann JM
    Food Drug Law J; 2015; 70(3):371-94, i. PubMed ID: 26630821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug safety relies on YOU, the healthcare professional, to find and report new serious adverse reactions.
    Jones JK
    Medscape J Med; 2008 Apr; 10(4):95. PubMed ID: 18504497
    [No Abstract]   [Full Text] [Related]  

  • 6. The practitioner's role in detection of adverse drug reactions.
    Soffer A
    Chest; 1984 Dec; 86(6):808-9. PubMed ID: 6548688
    [No Abstract]   [Full Text] [Related]  

  • 7. "Jake leg," other poisonings, physicians as canaries, and the FDA.
    Friedman E
    Medscape J Med; 2008 Apr; 10(4):103. PubMed ID: 18504500
    [No Abstract]   [Full Text] [Related]  

  • 8. Program seeks to enlist physicians to flag questionable promotion of drugs.
    Mitka M
    JAMA; 2010 Jul; 304(1):28-9. PubMed ID: 20606140
    [No Abstract]   [Full Text] [Related]  

  • 9. An evaluation of interventions designed to stimulate physician reporting of adverse drug events.
    Juergens JP; Szeinbach SL; Janssen MJ; Brown TR; Garner DD
    Top Hosp Pharm Manage; 1992 Jul; 12(2):12-8. PubMed ID: 10128725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adverse drug reaction processing in the United States and its dependence on physician reporting: zomepirac (Zomax) as a case in point.
    Corre KA; Spielberg TE
    Ann Emerg Med; 1988 Feb; 17(2):145-9. PubMed ID: 3257365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Introducing MEDWatch. A new approach to reporting medication and device adverse effects and product problems.
    Kessler DA
    JAMA; 1993 Jun; 269(21):2765-8. PubMed ID: 8492403
    [No Abstract]   [Full Text] [Related]  

  • 12. Drug Manufacturers' Delayed Disclosure of Serious and Unexpected Adverse Events to the US Food and Drug Administration.
    Ma P; Marinovic I; Karaca-Mandic P
    JAMA Intern Med; 2015 Sep; 175(9):1565-6. PubMed ID: 26214395
    [No Abstract]   [Full Text] [Related]  

  • 13. Indian College of Physicians (ICP) Position Statement on Pharmacovigilance.
    Dhamija P; Kalra S; Sharma PK; Kalaiselvan V; Muruganathan A; Balhara YPS; Badani R; Bantwal G; Das AK; Dhorepatil B; Ghosh S; Jeloka T; Khandelwal D; Nadkar MY; Patnaik KP; Saboo B; Sahay M; Sahay R; Tiwaskar M; Unnikrishnan AG
    J Assoc Physicians India; 2017 Mar; 65(3):63-66. PubMed ID: 28462545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monitoring drug safety--the power or the yellow form.
    Mehta U; Gunston G; O'Connor N
    S Afr Med J; 1998 Aug; 88(8):924. PubMed ID: 9754195
    [No Abstract]   [Full Text] [Related]  

  • 15. Physician knowledge, attitudes, and behavior related to reporting adverse drug events.
    Rogers AS; Israel E; Smith CR; Levine D; McBean AM; Valente C; Faich G
    Arch Intern Med; 1988 Jul; 148(7):1596-600. PubMed ID: 3382304
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Watching out for public safety.
    Laskin DM
    J Oral Maxillofac Surg; 1993 Sep; 51(9):959. PubMed ID: 8355100
    [No Abstract]   [Full Text] [Related]  

  • 17. Physicians' liability for adverse drug reactions.
    Kaufman MB; Stoukides CA; Campbell NA
    South Med J; 1994 Aug; 87(8):780-4. PubMed ID: 8052883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patterns in spontaneous adverse event reporting among branded and generic antiepileptic drugs.
    Bohn J; Kortepeter C; Muñoz M; Simms K; Montenegro S; Dal Pan G
    Clin Pharmacol Ther; 2015 May; 97(5):508-17. PubMed ID: 25670505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Towards the safer use of medicines.
    Asscher AW; Parr GD; Whitmarsh VB
    BMJ; 1995 Oct; 311(7011):1003-6. PubMed ID: 7580589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improving detection of adverse effects of marketed drugs.
    Klein DF; O'Brien CP
    JAMA; 2007 Jul; 298(3):333-4. PubMed ID: 17635895
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.